1-Methoxy-2-methyl-cyclohexan | 21547-36-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-Methoxy-2-methyl-cyclohexan
• 英文别名: cis-2-Methoxy-methylcyclohexan；(1S,2R)-1-methoxy-2-methylcyclohexane
• CAS: 21547-36-4；32122-44-4；53273-15-7；109238-86-0
• 化学式: C₈H₁₆O
• 分子量: 128.214
• InChiKey: QDLQQFYNFWYKPM-SFYZADRCSA-N

物化性质

• 沸点：
  142.9±8.0 °C(Predicted)
• 密度：
  0.85±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• NITROGEN-CONTAINING CYCLIC COMPOUND, COLOR CONVERSION FILM COMPRISING SAME, AND BACKLIGHT UNIT AND DISPLAY DEVICE COMPRISING SAME
  申请人：LG CHEM, LTD.

  公开号：US20190263836A1

  公开（公告）日：2019-08-29

  The present specification relates to a cyclic compound containing nitrogen, and a color conversion film, a backlight unit, and a display apparatus, including the same.

  本规范涉及含氮的环状化合物，以及包括该化合物的颜色转换膜、背光单元和显示装置。
• AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF
  申请人：Jung Grace

  公开号：US20110004006A1

  公开（公告）日：2011-01-06

  Aminocyclohexyl ether compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses uses for the compounds and compositions, including the treatment of arrhythmia.

  本发明公开了氨基环己基醚化合物。本发明的化合物可以用于组合物和试剂盒中。本发明还公开了该化合物和组合物的用途，包括治疗心律失常。
• Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
  申请人：Lycera Corporation

  公开号：US10364237B2

  公开（公告）日：2019-07-30

  The invention provides tetrahydroquinoline sulfonamide compounds, tetrahydronaphthalene sulfonyl compounds, and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.

  本发明提供了四氢喹啉磺酰胺化合物、四氢萘磺酸化合物和相关化合物、药物组合物、促进RORy活性的方法、增加受试者体内IL-17含量的方法，以及使用此类化合物治疗癌症和其他疾病的方法。
• [EN] BIPHENYL DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] INHIBITEUR DE DÉRIVÉ BIPHÉNYLE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 联苯类衍生物抑制剂、其制备方法和应用
  申请人：SHANGHAI HANSOH BIOMEDICAL CO LTD

  公开号：WO2021136354A1

  公开（公告）日：2021-07-08

  一种通式(Ib)所示的联苯类衍生物抑制剂及其在制备治疗癌症、感染性疾病、自身免疫性疾病药物中的用途。
• Adoptive Cellular Therapy Using an Agonist of Retinoic Acid Receptor-Related Orphan Receptor Gamma & Related Therapeutic Methods
  申请人：LYCERA CORPORATION

  公开号：US20170007686A1

  公开（公告）日：2017-01-12

  The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (RORγ) and provides adoptive cellular therapies using an agonist of RORγ, populations of lymphocyte cells that have been exposed to an agonist of RORγ, populations of dendritic cells that have been exposed to an agonist of RORγ, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and/or dendritic cells in a patient by administering an agonist of RORγ to a patient.